Molecular alterations in partially-encapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma

Thyroid

Volumn 23, Issue 10, 2013, Pages 1256-1262

  Howitt, Brooke E ^a   Jia, Yonghui ^a   Sholl, Lynette M ^a   Barletta, Justine A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; RAF PROTEIN; RAS PROTEIN;

ADULT; CANCER RISK; CLINICAL ARTICLE; CLINICAL FEATURE; CONFERENCE PAPER; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS POTENTIAL; MOLECULAR DIAGNOSIS; MUTATIONAL ANALYSIS; ONCOGENE RAS; PARTIALLY ENCAPSULATED FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA; PRIORITY JOURNAL; THYROID CARCINOMA; TUMOR RECURRENCE; WELL CIRCUMSCRIBED FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA;

ADULT; AGED; AMINO ACID SUBSTITUTION; BOSTON; CARCINOMA, PAPILLARY, FOLLICULAR; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; RETROSPECTIVE STUDIES; THYROID GLAND; THYROID NEOPLASMS; TUMOR BURDEN; YOUNG ADULT;

EID: 84884668461     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0018     Document Type: Conference Paper

References (54)

1. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167.
2. Chen AY, Jemal A, Ward EM 2009 Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 115:3801-3807.
3. Yu GP, Li JC, Branovan D, McCormick S, Schantz SP 2010 Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups. Thyroid 20:465-473.
4. Siegel R, Naishadham D, Jemal A 2012 Cancer statistics, 2012. CA Cancer J Clin 62:10-29.
5. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM 1998 Intermediate and long-term side effects of high-dose radio-iodine therapy for thyroid carcinoma. J Nucl Med 39:1551-1554.
6. Almeida JP, Sanabria AE, Lima EN, Kowalski LP 2011 Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head Neck 33:686-690.
7. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD 2008 The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93:504-515.
8. Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I 2011 Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 117:4439-4446.
9. Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scelo G, Pukkala E, Hemminki K, Anderson A, Tracey E, Friis S, McBride ML, Kee-Seng C, Pompe-Kirn V, Kliewer EV, Tonita JM, Jonasson JG, Martos C, Boffetta P, Brennan P 2006 Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab 91:1819-1825.
10. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP 2009 Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19:451-457.
11. Suster S 2006 Thyroid tumors with a follicular growth pattern: problems in differential diagnosis. Arch Pathol Lab Med 130:984-988.
12. Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J 1985 Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 55:805-828.
13. Lin HW, Bhattacharyya N 2010 Clinical behavior of follicu-lar variant of papillary thyroid carcinoma: presentation and survival. Laryngoscope 120:712-716.
14. Passler C, Prager G, Scheuba C, Niederle BE, Kaserer K, Zettinig G, Niederle B 2003 Follicular variant of papillary thyroid carcinoma: a long-term follow-up. Arch Surg 138: 1362-1366.
15. Sebastian SO, Gonzalez JM, Paricio PP, Perez JS, Flores DP, Madrona AP, Romero PR, Tebar FJ 2000 Papillary thyroid carcinoma: prognostic index for survival including the his-tological variety. Arch Surg 135:272-277.
16. Tielens ET, Sherman SI, Hruban RH, Ladenson PW 1994 Follicular variant of papillary thyroid carcinoma. A clinico-pathologic study. Cancer 73:424-431.
17. Lang BH, Lo CY, Chan WF, Lam AK, Wan KY 2006 Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and longterm outcome. World J Surg 30:752-758.
18. Liu J, Singh B, Tallini G, Carlson DL, Katabi N, Shaha A, Tuttle RM, Ghossein RA 2006 Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 107:1255-1264.
19. Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Ghossein RA 2010 Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histo-logical subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23: 1191-1200.
20. Rivera M, Tuttle RM, Patel S, Shaha A, Shah JP, Ghossein RA 2009 Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern). Thyroid 19:119-127.
21. Gupta S, Ajise O, Dultz L, Wang B, Nonaka D, Ogilvie J, Heller KS, Patel KN 2012 Follicular variant of papillary thyroid cancer: encapsulated, nonencapsulated, and diffuse: distinct biologic and clinical entities. Arch Otolaryngol Head Neck Surg 138:227-233.
22. Eloy C, Santos J, Soares P, Sobrinho-Simoes M 2011 The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch 459:265-276.
23. Piana S, Frasoldati A, Di Felice E, Gardini G, Tallini G, Rosai J 2010 Encapsulated well-differentiated follicular-patterned thyroid carcinomas do not play a significant role in the fatality rates from thyroid carcinoma. Am J Surg Pathol 34: 868-872.
24. Ghossein R 2010 Encapsulated malignant follicular cell-derived thyroid tumors. Endocr Pathol 21:212-218.
25. Nikiforov YE 2011 Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 135:569-577.
26. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457.
27. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627.
28. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE 2006 Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216-222.
29. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA 1997 Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57:1690-1694.
30. Karga H, Lee JK, Vickery AL Jr, Thor A, Gaz RD, Jameson JL 1991 Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab 73:832-836.
31. Ezzat S, Zheng L, Kolenda J, Safarian A, Freeman JL, Asa SL 1996 Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid 6:409-416.
32. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404.
33. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, 2nd, Tallini G, Kroll TG, Nikiforov YE 2003 RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88: 2318-2326.
34. French CA, Alexander EK, Cibas ES, Nose V, Laguette J, Faquin W, Garber J, Moore F Jr, Fletcher JA, Larsen PR, Kroll TG 2003 Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 162:1053-1060.
35. Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G, Hoog A, Frisk T, Larsson C, Zedenius J 2003 Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin En-docrinol Metab 88:4440-4445.
36. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Ni-kiforov YE 2002 PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26:1016-1023.
37. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, Leite V 2002 Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87:3947-3952.
38. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262.
39. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE 2003 Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120:71-77.
40. Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovisco V, Vieira de Castro I, Cardoso-de-Oliveira M, Fon-seca E, Soares P, Sobrinho-Simoes M 2006 PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91:213-220.
41. Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK 2010 Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer 116:2974-2983.
42. Wreesmann VB, Ghossein RA, Hezel M, Banerjee D, Shaha AR, Tuttle RM, Shah JP, Rao PH, Singh B 2004 Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity. Genes Chromosomes Cancer 40:355-364.
43. Vivero M, Kraft S, Barletta J 2013 Risk stratification of fol-licular variant of papillary thyroid carcinoma. Thyroid 23: 273-279.
44. LiVolsi VA 2003 Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 98:1997; author reply 1997-1998.
45. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M, Bussolati G, Rosai J 2007 Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 31:1256-1264.
46. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, Fiorentino M, Rubin MA, Polyak K, Chan J, Wang Y, Fletcher JA, Santa-gata S, Corso G, Roviello F, Shivdasani R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, Meyerson ML, Garraway LA 2009 Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 4:e7887.
47. Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, Marchetti A, Borsu L, Barr FG, Ladanyi M 2012 Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res 18:748-757.
48. Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, von Deimling A, Birner P, Preusser M 2012 Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 36:844-850.
49. van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA, Schouten LJ, Gorissen HJ, Schalken JA, van den Brandt PA, Oosterwijk E 2005 Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer 5:57.
50. Hunt JL, Yim JH, Tometsko M, Finkelstein SD, Swalsky P, Carty SE 2003 Loss of heterozygosity of the VHL gene identifies malignancy and predicts death in follicular thyroid tumors. Surgery 134:1043-1047; discussion 1047-1048.
51. Ivanova R, Soares P, Castro P, Sobrinho-Simoes M 2002 Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohisto-chemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. Virchows Arch 440:418-424.
52. Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, Chan JK, DeLellis RA, Harach HR, Kakudo K, LiVolsi VA, Rosai J, Sebo TJ, Sobrinho-Simoes M, Wenig BM, Lae ME 2004 Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28:1336-1340.
53. Daniels GH 2011 What if many follicular variant papillary thyroid carcinomas are not malignant? A review of follicular variant papillary thyroid carcinoma and a proposal for a new classification. Endocr Pract 17:768-787.
54. Salajegheh A, Petcu EB, Smith RA, Lam AK 2008 Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists. Postgrad Med J 84: 78-82.